Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14413MR)

This product GTTS-WQ14413MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14413MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6372MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ4359MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ5472MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ1372MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ14436MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ4776MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ7131MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ12691MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-21M18
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW